Wegovy for beginners: what the evidence actually says before you start

Wegovy is a GLP-1 receptor agonist: it mimics a gut hormone that slows gastric emptying, increases fullness, and reduces appetite signals reaching the brain.
Treatment begins at 0.25mg (a starting dose chosen for tolerability, not weight loss) and is titrated by your prescriber roughly every four weeks up to the 2.4mg maintenance dose.
The most common early side effects are gastrointestinal: nausea, constipation, loose stools, or indigestion, typically most noticeable after starting or stepping up, and often settling within days to two weeks.
Wegovy is not available on the NHS for most adults yet; private treatment through a GPhC-registered pharmacy is the current route for the majority of people who qualify.

Wegovy (semaglutide 2.4mg) is a once-weekly injection licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. In the STEP 1 clinical trial, participants lost an average of around 15% of their body weight over 68 weeks — a figure published in the New England Journal of Medicine and cited by NICE in its appraisal of the medicine. This is a prescription-only medicine, which means a prescriber assesses your suitability before any treatment begins. If you are new to it, the most useful thing to know up front is that the first few weeks look very different from the maintenance phase — and understanding that difference makes the whole process easier to navigate.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How Wegovy works, what the first month feels like, and what beginners most often get wrong

What the trial data tells beginners about realistic expectations

The STEP 1 trial is the best place to start because it sets honest expectations. Participants (adults with obesity or overweight and at least one weight-related condition, without diabetes) lost an average of roughly 15% of body weight over 68 weeks alongside a reduced-calorie diet and increased activity. That is a meaningful result, but 68 weeks is over a year. Weight loss in the first month, while real for many people, is modest compared with what accumulates over the full titration period.

The titration schedule itself is the reason for this. The NHS medicines page for semaglutide describes the step-up pathway: 0.25mg, then 0.5mg, then 1mg, then 1.7mg, then 2.4mg as the maintenance dose, each step typically held for around four weeks. The appetite-reducing effect builds as the dose rises. People who expect dramatic results from pen one (the 0.25mg pen) are almost always disappointed, and often needlessly so. The starter dose exists to settle the body into the medicine, full stop.

NICE recommended semaglutide (Wegovy) for eligible adults in its appraisal TA875, specifically within specialist weight management services and for a maximum of two years. That framing matters for beginners: this is a medium-term treatment with lifestyle changes running alongside it, not a short course.

What beginners feel in the early weeks, and which side effects ease on their own

Nausea is the side effect new starters mention most. It tends to peak in the first few days after an injection and often fades before the next dose is due. Eating smaller portions, avoiding rich or fatty food around injection day, and drinking plenty of water all help, and your prescriber or the Patient Information Leaflet can give specific guidance on managing it.

Constipation is the other common early complaint. Fibre, fluid, and keeping moving matter more than usual. Some people find the opposite: loose stools or stomach cramps for a day or two after each step-up. Both patterns tend to settle once the body adjusts to the new dose level.

One area worth reading about before you start: Wegovy interacts with how quickly other medicines are absorbed because it slows gastric emptying. If you take blood-thinning medicines, for example, it is worth reading about taking Wegovy on blood thinners so you can have an informed conversation with your prescriber before you begin, and people sometimes also wonder whether Wegovy itself is a blood thinner, which is a separate question worth understanding before your first injection. Similarly, women using oral contraceptives should discuss options with their prescriber, as absorption of the pill may be affected.

Urgent help is needed for severe, persistent stomach pain that radiates to the back, this can be a sign of pancreatitis, which the MHRA flagged as a known but infrequent risk in a January 2026 Drug Safety Update. It is uncommon, but beginners should know the symptom. Any suspected side effects can be reported at the MHRA's Yellow Card scheme.

Injection sites, storage, and the practical setup most people overlook

Wegovy is injected subcutaneously (into the fat layer just below the skin) once a week. The three approved sites are the abdomen, the outer thigh, and the upper arm. Rotating between sites each week reduces the chance of skin irritation at any one spot. Some people find the thigh practical for self-injection; our page on injecting into the inner thigh covers technique questions beginners often ask.

Storage matters more than many starters realise. Pens must be kept refrigerated at 2–8°C; the exact room-temperature window once removed from the fridge is set out in the Patient Information Leaflet and varies, so check that rather than relying on general memory. If you are planning a holiday or a work trip, factor in how you will keep pens cool, worth thinking through before the first pen arrives rather than the night before you leave.

Pick a consistent day of the week. Many people choose a Monday so the injection routine is anchored to the start of the week, or a Friday if they want the first day or two of any nausea to fall over a weekend rather than a working day. Timing relative to payday or a monthly delivery schedule can also help with planning repeats.

Who can get Wegovy privately and how the clinical assessment works

Private eligibility follows the licensed criteria: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. BMI alone is not enough to guarantee a prescription, the prescriber looks at the whole picture, including other medicines, relevant medical history, and whether there are any contraindications. Wegovy is not recommended during pregnancy, breastfeeding, or when trying to conceive, and it is not licensed for people under 18.

If you are weighing up whether Wegovy or Mounjaro is the right fit, our Wegovy suitability guide walks through the clinical factors a prescriber considers. Cost is one practical variable; a realistic overview of what private treatment runs to is covered on our Wegovy price page. For a broader look at semaglutide as a medicine, the semaglutide overview covers both its weight-management and other licensed uses.

At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day, a named clinician, not software. Orders placed before midday Monday to Friday are dispatched the same day once clinically approved, arriving with DPD the next working day in plain packaging. If you are ready to find out whether you qualify, you can start your free consultation with our clinical team.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions